"For now, the appropriate way to act on this work is to ensure that people with colon cancer who also have obesity or diabetes are offered guideline-supported metabolic therapies, including GLP-1 agents when clinically indicated, as part of comprehensive care." The researcher emphasized that this is a "hopeful signal rather than a final answer." "It suggests that we may be able to improve cancer outcomes by treating the whole person and not just the tumor, and that modern metabolic therapies could have unanticipated benefits for patients with malignancy," he said
A calculator helps you change the draw volume into units, so the syringe marking is easier to understand
Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity
The Codeage liposomal formula costs more but delivers meaningfully better bioavailability through its phospholipid encapsulation technology
But, based on what we know so far, it might be reasonably expected that there would be benefits to kidney health from their use, says Dr
Semaglutide is a medication commonly used to treat type 2 diabetes and assist with weight management